|
1
|
de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
2
|
Giacchetti S, Perpoint B, Zidani R, et al:
Phase III multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 18:136–147. 2000.
|
|
3
|
Cersosimo RJ: Oxaliplatin-associated
neuropathy: a review. Ann Pharmacother. 39:128–135. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adelsberger H, Quasthoff S, Grosskreutz J,
Lepier A, Eckel F and Lers C: The chemotherapeutic oxaliplatin
alters voltage-gated Na(+) channel kinetics on rat sensory neurons.
Eur J Pharmacol. 406:25–32. 2000.PubMed/NCBI
|
|
5
|
Gauchan P, Andoh T, Ikeda K, et al:
Mechanical allodynia induced by paclitaxel, oxaliplatin and
vincristine: different effectiveness of gabapentin and different
expression of voltage-dependent calcium channel alpha(2)delta-1
subunit. Biol Pharm Bull. 32:732–734. 2009. View Article : Google Scholar
|
|
6
|
Grolleau F, Gamelin L, Boisdron-Celle M,
Lapied B, Pelhate M and Gamelin E: A possible explanation for a
neurotoxic effect of the anticancer agent oxaliplatin on neuronal
voltage-gated sodium channels. J Neurophysiol. 85:2293–2297.
2001.PubMed/NCBI
|
|
7
|
Cascinu S, Catalano V, Cordella L, et al:
Neuroprotective effect of reduced glutathione on oxaliplatin-based
chemotherapy in advanced colorectal cancer: a randomized,
double-blind, placebo controlled trial. J Clin Oncol. 16:3478–3483.
2002. View Article : Google Scholar
|
|
8
|
Eckel F, Schmelz R, Adelsberger H, Erdmann
J, Quasthoff S and Lersch C: Prevention of oxaliplatin neuropathy
by carbamazepine. A pilot study. Dtsch Med Wochenschr. 127:78–82.
2003. View Article : Google Scholar
|
|
9
|
Mariani G, Garrone O, Granetto C, Numico
G, LaCiura P and Grecchi G: Oxaliplatin induced neuropathy: could
gabapentin be the answer? Proc Am Soc Clin Oncol. 19:abs. 2397.
2000.
|
|
10
|
Penz M, Kornek GV, Raderer M, Ulrich-Pur
H, Fiebiger W and Scheithauer W: Subcutaneous administration of
amifostine: a promising therapeutic option in patients with
oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol.
12:421–422. 2001. View Article : Google Scholar
|
|
11
|
Agafitei RD, Schneider S, Iqbal S, Yang D,
Groshen S and Lenz HJ: Effect of celecoxib on neurotoxicity in
patients with metastatic colorectal cancer treated with
5-FU/oxaliplatin (CIFOX). J Clin Oncol. 22:36002004.
|
|
12
|
Muto O, Ando H, Ono T, et al: Reduction of
oxaliplatin-related neurotoxicity by calcium and magnesium
infusions. Gan To Kagaku Ryoho. 34:579–581. 2007.PubMed/NCBI
|
|
13
|
Gamelin L, Boisdron-Celle M, Delva R, et
al: Prevention of oxaliplatin-related neurotoxicity by calcium and
magnesium infusions: a retrospective study of 161 patients
receiving oxaliplatin combined with 5-fluorouracil and leucovorin
for advanced colorectal cancer. Clin Cancer Res. 10:4055–4061.
2004. View Article : Google Scholar
|
|
14
|
Hochster HS, Grothey A and Childs BH: Use
of calcium and magnesium salts to reduce oxaliplatin-related
neurotoxicity. J Clin Oncol. 25:4028–4029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurniali PC, Luo LG and Weitberg AB: Role
of calcium/magnesium infusion in oxaliplatin-based chemotherapy for
colorectal cancer patients. Oncology. 24:289–292. 2010.PubMed/NCBI
|
|
16
|
Khattak MA: Calcium and magnesium
prophylaxis for oxaliplatin-related neurotoxicity: is it a tradeoff
between drug efficacy and toxicity? Oncologist. 16:1780–1783. 2011.
View Article : Google Scholar
|
|
17
|
Jadad AR, Moore RA, Carroll D, et al:
Assessing the quality of reports of randomized clinical trials: is
blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
|
|
18
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grothey A, Nikcevich DA, Sloan JA, et al:
Intravenous calcium and magnesium for oxaliplatin-induced sensory
neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol.
29:421–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong M, Xing PY, Liu P, Feng FY and Shi
YK: Assessment of the protective effect of calcium-magnesium
infusion and glutathione on oxaliplatin-induced neurotoxicity.
Zhonghua Zhong Liu Za Zhi. 32:208–211. 2010.PubMed/NCBI
|
|
21
|
Ishibashi K, Okada N, Miyazaki T, Sano M
and Ishida H: Effect of calcium and magnesium on neurotoxicity and
blood platinum concentrations in patients receiving mFOLFOX6
therapy: a prospective randomized study. Int J Clin Oncol.
15:82–87. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chay WY and Tan SH: Use of calcium and
magnesium infusions in prevention of oxaliplatin induced sensory
neuropathy. Asia-Pacific J Clin Oncol. 6:270–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Andre T, Boni C, Mounedji-Boudiaf L, et
al: Oxalipatin, fluorouracil, and leucovorin as adjuvant treatment
for color cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar
|
|
25
|
Knijn N, Tol J, Koopman M, et al: The
effect of prophylactic calcium and magnesium infusions on the
incidence of neurotoxicity and clinical outcome of
oxaliplatin-based systemic treatment in advanced colorectal cancer
patients. Eur J Cancer. 47:369–374. 2011. View Article : Google Scholar
|
|
26
|
Gamelin L: Oxaliplatin-related
neurotoxicity: interest of calcium-magnesium infusion and no impact
on its efficacy. J Clin Oncol. 26:1189–1190. 2008. View Article : Google Scholar : PubMed/NCBI
|
